ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.

A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.

A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.

September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.

Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.